item management s discussion and analysis of financial condition and results of operations the following discussion and analysis should be read in conjunction with the financial statements and notes thereto included elsewhere in this annual report on form k 
special note certain statements set forth below constitute forward looking statements within the meaning of section a of the securities act of  as amended  and the securities exchange act of  as amended 
see business special note regarding forward looking statements 
overview urocor provides a broad range of diagnostic services for the clinical management of certain urological cancers and complex diseases 
the company complements its diagnostic services by marketing and co promoting therapeutic products for certain of these diseases 
the company also is developing and offering related information services intended to enhance and expand services to its clients 
the company has established four business groups  urodiagnostics  urosciences  urotherapeutics and disease management information systems  to serve the needs of urologists and managed care organizations for the diagnostic  prognostic and therapeutic care of patients throughout the entire course of their diseases 
the company currently derives substantially all of its revenue from diagnostic products and services that its urodiagnostics group provides to the urology market to assist in the diagnosis  prognosis and management of prostate cancer  bladder cancer and kidney stones disease 
the company recognizes revenue when products are sold or services are rendered 
the company typically bills various third party payors for its products and services  including governmental programs such as medicare  private insurance and managed care plans  as well as individual patients 
for the year ended december   approximately   and of the company s revenue was attributable to medicare  private insurance and managed care  individual patients  and physicians and hospitals  respectively 
in  the company acquired co promotion rights to two therapeutic products and began marketing these products to urologists 
the company also has distribution rights for another therapeutic product  currently under review for marketing approval by the fda 
results of operations the following table sets forth certain operating data expressed as a percentage of revenue for each period indicated year ended december  revenue operating expenses direct cost of services and products selling  general and administrative expenses research and development total operating expenses income from operations other income expense income before income taxes income taxes net income year ended december  compared to year ended december  revenue 
revenue increased  from approximately million in to approximately million in this increase was due primarily to a increase in case volume attributable to expansion of the company s client base from  to  urologists in december and  respectively  increased utilization of the company s diagnostic products and services by existing clients and increased utilization of the company s kidney stone product line 
case volume increased at a higher rate than revenue primarily due to the continued expansion of the kidney stone product line introduced in and an increase in serum based tests  each of which generally has lower average selling prices than those of most of the company s other products 
direct cost of services and products 
direct cost of services and products increased  from approximately million in to approximately million in this increase was due principally to higher personnel costs and supply and distribution costs  resulting primarily from increased case volume and service enhancement initiatives 
as a percentage of revenue  direct expenses increased to for compared to in this increase was due principally to continued growth of the company s kidney stone and serum based tests  each of which has lower profit margins than most of the company s other products 
selling  general and administrative expenses 
selling  general and administrative expenses increased  from approximately million in to approximately million in this increase was due principally to higher personnel costs related to expansion of marketing  sales staff and management information services personnel  increased provision for doubtful accounts due principally to higher revenues and increased accounts receivable and expanded investor relations activities 
in the fourth quarter of  the company increased the provision for doubtful accounts by an additional  charge beyond the normal level of provision 
as a percentage of revenue  selling  general and administrative expenses increased to for compared to in research and development 
research and development expenses decreased  from approximately million in to approximately million in this decrease was due primarily to timing of completed external research activities 
as a percentage of revenue  research and development expenses decreased to for compared to in other income expense 
interest income increased from approximately million in to approximately million in due principally to the increase in cash  cash equivalents  and investments resulting from a full year of proceeds of the company s initial public offering of common stock in may interest expense decreased  from approximately  in to approximately  in  due primarily to a decrease in obligations under capitalized leases and the repayment of the company s bank credit facility  which the company did not renew upon its expiration in february the company had no borrowings under the facility during  but had borrowings thereunder during income taxes 
income tax benefits of million for reflected a one time benefit to record the future tax benefits of loss carryforwards and other deferred tax items 
earnings in future periods will include federal and state income tax provisions  currently estimated at of pretax income 
year ended december  compared to year ended december  revenue 
revenue increased  from approximately million in to approximately million in this increase was due primarily to a increase in case volume attributable to expansion of the company s client base from  to  urologists in december and  respectively  increased utilization of the company s diagnostic products and services by existing clients  and the introduction of the company s new kidney stone product line in february case volume increased at a higher rate than revenue primarily due to the shift in product and price mix resulting from the introduction of the kidney stone product line and an increase in serum based tests  each of which generally have lower average selling prices than those of most of the company s other services 
direct cost of services and products 
direct cost of services and products increased  from approximately million in to approximately million in this increase was due principally to higher personnel  supply and shipping costs resulting from increased case volume 
as a percentage of revenue  direct expenses increased to for compared to in this increase was due principally to the introduction of the company s new kidney stone product line in early and an increase in serum based tests  each of which have lower profit margins than most of the company s other services 
selling  general and administrative expenses 
selling  general and administrative expenses increased  from approximately million in to approximately million in this increase was due principally to increased personnel costs related to marketing  sales staff and information services personnel  increases in insurance  taxes and professional services and increases in promotional expenses related to new product introductions 
as a percentage of revenue  selling  general and administrative expenses were for compared to in research and development 
research and development expenses increased  from approximately million in to approximately million in this increase was due principally to increased internal research laboratory personnel costs  offset by a decrease in costs associated with certain external collaborative research projects completed in that were sponsored and funded by the company 
as a percentage of revenue  research and development expenses were for compared to in other income expense 
interest income increased from approximately  in to approximately million in due principally to the increased cash  cash equivalents  and investments that resulted from the proceeds from the company s initial public offering of common stock in may interest expense decreased  from approximately  in to approximately  in  due primarily to a decrease in average principal balance of a bank credit facility during quarterly results of operations the following table presents the company s results of operations for the last calendar quarters 
this data is unaudited and includes  in the opinion of the company s management  all adjustments necessary to present fairly the data in accordance with generally accepted accounting principles 
such quarterly results are not necessarily indicative of future results of operations 
the company s quarterly operating results are affected by a wide variety of factors  many of which are outside the company s control  that could materially and adversely affect revenue  operating expenses and income 
these factors include the volume and timing of cases received  seasonality related to the timing of patient visits to the urologist s office as affected by weather and insurance deductible status  competitive pricing pressures  availability and cost of diagnostic supplies  availability and cost of logistic services  changes in the mix of products sold  the complexity of accounts receivable collection  the timing and costs of new product and technology introductions by the company or its competitors  retention and expansion of the company s sales force and timing of payments from medicare and other third party payors 
the company s results of operations for the fourth quarter of include a million income tax benefit and a charge of  to increase the allowance for doubtful accounts 
dollars in thousands q q q q q q q q revenue         operating expenses direct costs of services and products         selling  general and administrative expenses         research and development income from operations other income expense income before income taxes  income tax benefit net income  q q q q revenue     operating expenses direct costs of services and products     selling  general and administrative expenses     research and development income from operations other income expense income before income taxes  income tax benefit  net income   liquidity and capital resources as of december   the company had cash and cash equivalents of approximately million  short term marketable investments of million and long term marketable investments of approximately million 
such marketable investments consisted principally of high grade fixed income securities  with a maturity of less than two years 
as of december   the company s working capital was approximately million 
accounts receivable  net of allowance for doubtful accounts  totaled approximately million at december   an increase of approximately million from december  or 
at december   the company s average number of days sales in receivables was approximately compared to approximately at december  during and  the company s medicare intermediary and certain other third party payors continued a general trend of increasing the time between receipt of claims for reimbursement and payment to the company 
the increase in accounts receivable for was due primarily to payor delays caused by systems changes enacted by several of the company s larger payors as well as additional documentation requirements imposed by medicare and other third party payors which further complicated the billing process 
the company is working with these payors and its physician clients to resolve billing and payment systems  documentation and related processing issues 
in an effort to reduce its average number of days sales in receivables  the company has implemented staffing  systems and process changes and is undertaking additional initiatives intended to improve the results of its claims and collections efforts 
the company monitors the collection quality of its accounts receivable through analytical review of aging categories by payor group and collections performance compared to historical trends 
the company maintains what it believes to be an adequate level of an allowance for doubtful accounts through charges to operations which are included in selling  general and administrative expenses 
in the fourth quarter of  such charges included an additional  provision to increase the allowance for doubtful accounts beyond the normal level of such provisions 
operating activities used net cash of approximately million in  provided net cash of approximately  in and used net cash of approximately  in the net cash used by operating activities in was primarily the result of net income of approximately million and depreciation and amortization of approximately million offset in part by an approximately million increase in accounts receivable  an approximately million benefit from deferred income taxes and an approximately  decrease in accrued compensation 
the deferred tax benefit was the result of a decrease in the valuation allowance related to net deferred tax assets due to utilization of part of the net operating loss carryforward by the company s operations and due to management s reassessment of the company s ability to realize its remaining net deferred tax asset based upon its history of operating results for and and projected operating results for accrued compensation decreased because the company did not accrue a management bonus for and did accrue a bonus for net cash used by investing activities for was approximately million and consisted primarily of capital expenditures of approximately and purchases of short term investments of approximately million  offset by maturities of long term investments of approximately million 
net cash provided by financing activities was approximately  for  consisting primarily of exercises of stock warrants of approximately  and stock options of approximately  offset by principal payments under capital leases and other indebtedness of approximately  the company s capital expenditures of approximately million in were primarily for computer hardware and software  furniture and fixtures and software development for the company s information services 
of the total amount  approximately million related to internal software development costs for information services 
while future capital expenditures will depend upon a number of factors  the level of expenditures is expected to be higher than the historical level of such expenditures as the company expands to deliver therapeutics and information services and continues to enhance current diagnostic services and operational capabilities 
the company intends to finance the majority of these capital expenditures with existing cash and investment balances 
in december  the company obtained distribution rights to a therapeutic product currently under review for marketing approval by the fda 
the total cost of the distribution rights is million  which is payable in installments based on achievement of certain milestones by the manufacturer 
the company made an initial payment of  in december and a second installment of  in after the product was submitted for fda review in april the company is obligated to pay an additional milestone payment of million if and when the product is approved by the fda for marketing in the united states 
if the company makes this payment in  it intends to make any such payment from existing cash and investment balances 
the company paid current income taxes of approximately  during at december   the company estimated net operating loss carryforwards of approximately million were available to reduce future taxable income after considering certain annual limitations 
the company believes that its existing capital resources will be sufficient to provide the funds necessary to maintain its present level of operations and implement its currently planned growth strategy 
however  there may be circumstances or new business opportunities that would require additional resources 
in such event  the company may be required to seek additional financing  and there is no assurance that the company would be able to obtain such financing on acceptable terms 
the company believes that it has prepared its computer systems and related applications to accommodate date sensitive information relating to the year the company expects that any additional costs related to ensuring such systems and applications are year compliant will not be material to its financial condition or results of operations 
item a 
quantitative and qualitative disclosures about market risk not applicable 

